Gan & Lee Pharmaceuticals (SHA: 603087), a leading pharmaceutical company, has announced that it has received registration approval from Algerian authorities for two of its insulin products: the insulin aspart injection pre-filled pen and the insulin aspart 30 injection pre-filled pen. These products are slated to be manufactured locally by Algeria-based Biocare Biotech, marking a significant step in expanding access to diabetes care in the region.
Algeria, the largest country in Africa by land area, is home to a population of 45.61 million people with a per capita GDP of USD 5,260.2. The country faces a significant burden of diabetes, with the 10th edition of the IDF Diabetes Atlas indicating that there are 2.01 million adults aged 20 to 79 living with the condition, equating to a prevalence rate of 7.4%. The approval and local production of Gan & Lee’s insulin products are expected to contribute to addressing the needs of this patient population.- Flcube.com
